CTRI/2020/11/028801已完成未知
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) And both active treatments to a placebo control in the treatment of acne vulgaris
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy male or non pregnant female aged ââ?°Â¥ 12 and ââ?°Â¤ 40 years with a clinical diagnosis of acne vulgaris.
- •2. Subjects who are 18 years of age or older (up to the age of 40) must have provided IRB approved written informed consent. Subjects 12 to 17 years of age.inclusive must have provided IRB approved written assent; this written assent must be accompanied by an IRB approved written informed consent from the Subjectââ?¬•s legally acceptable representative (i.e., parent or guardian). In addition, all Subjects or their legally acceptable representatives (i.e., parent or guardian) must sign a HIPAA authorization, if applicable.
- •3. Subjects must have ââ?°Â¥ 25 non-inflammatory lesions (i.e., open and closed comedones) AND ââ?°Â¥ 20 inflammatory lesions (i.e., papules and pustules) AND ââ?°Â¤2 nodulocystic lesions (i.e., nodules and cysts), at baseline on the face. For the purposes of study treatment and evaluation, these lesions will be limited to the facial treatment area. All lesions will be counted, including those present on the nose. Lesions involving the eyes, lips and scalp should be excluded from the count. Subjects may have acne lesions on other areas of the body which will also be excluded from the count, treatment, and the Investigatorââ?¬•s Global Assessment (IGA) evaluation (e.g., on the back, chest and arms).
- •4. Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the Investigatorââ?¬•s Global Assessment (IGA).
- •5. Subjects must be willing to refrain from using all other topical acne medications or antibiotics for acne vulgaris during the 12-week treatment period, other than the investigational product.
- •6. Female Subjects of childbearing potential (excluding women who are or premenarchal, surgically sterilized or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study from the day of the first dose administration to 30 days after the last administration of study drug. A sterile sexual partner is NOT considered an adequate form of birth control.
- •7. All male Subjects must agree to use accepted methods of birth control with their
- •partners. Female partners should use an acceptable method of birth control.
- •8. Subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits.
- •9. Subjects must be in good health and free from any clinically significant disease, including but not limited to, conditions that may interfere with the evaluation of acne vulgaris.
- •10. Subjects who use make-up must have used the same brands/types of make-up for a minimum period of 14 days prior to study entry and must agree to not change make-up brand/type or frequency of use throughout the study.
排除标准
- •1. Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.
- •2. Subjects with a history of hypersensitivity or allergy to adapalene, retinoids and/or any of the study medication ingredients, have a known hypersensitivity to adapalene and benzoyl peroxide and its excipients.
- •3. Subjects with the presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneiform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).
- •4. Subjects with excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris.
- •5. Subjects who have performed wax depilation of the face within 14 days prior to baseline.
- •6. Subjects who have used within 6 months prior to baseline or use during the study of oral retinoids or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
- •7. Subjects who have used estrogens or oral contraceptives for less than 3 months prior to baseline; use of such therapy must remain constant throughout the study.
- •8. Subjects who have used procedures such as cryodestruction or chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional steroids, or f. X-ray therapy on the face within 1 month prior to baseline or use during the study.
- •9. Subjects who have used treatments within 1 month prior to baseline or during the study: such as systemic steroids, systemic antibiotics, systemic treatment for acne vulgaris (other than oral retinoids, which require a 6-month washout), or systemic anti-inflammatory agents. If Subject uses a systemic anti-inflammatory product during the study, the Principal Investigator will judge if this protocol violation is clinically significant, :
- •10. Subjects who have used treatments such as topical steroids,topical retinoids, topical acne treatments including over-the-counter preparations, topical anti-inflammatory agents, or topical antibiotics within 2 weeks prior to baseline or during the study.
- •11. Subjects who have received radiation therapy and/or anti-neoplastic agents within 90 days prior to baseline.
- •12. Subjects who have unstable medical disorders that are clinically significant or have life threatening diseases.
- •13. Subjects who have on-going malignancies requiring systemic treatment will be excluded from study participation. In addition, Subjects who have any malignancy of the skin of the facial area will also be excluded.
- •14. Subjects who engage in activities that involve excessive or prolonged exposure to sunlight or weather extremes, such as wind or cold.
- •15. Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or use drugs of abuse (including, but not limited to, cannabinoids, cocaine and barbiturates).
- •16. Subjects who have participated in an investigational drug study (i.e., Subjects have been treated with an investigational drug) within 30 days prior to baseline will be excluded from study participation. Subjects who are participating in non-treatment studies such as observational studies or registry studies can be considered for inclusion.
- •17. Subjects who have been previously enrolled in this study.
研究者
相似试验
进行中（未招募）
不适用
A multi-center, double-blind, randomized, placebo controlled, dose-ranging phase 2 study to investigate pharmacodynamics, safety, tolerability and pharmacokinetics of RO5073031 in patients with type 2 diabetes mellitus treated with a stable dose of metformin (BC20688)EUCTR2006-004407-19-LTF. Hoffmann-La Roche Ltd264
进行中（未招募）
1 期
Coronary computed tomography study to assess the effect of inclisiran on atherosclerotic plaque progression in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular eventson-obstructive coronary artery diseaseMedDRA version: 20.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2021-004601-47-IEovartis Pharma AG600
进行中（未招募）
1 期
Efficacy and Safety study of CSJ148 in stem cell transplant patientshuman cytomegalovirus (HCMV) in stem cell transplant patientsMedDRA version: 17.1Level: LLTClassification code 10009703Term: CMV infectionSystem Organ Class: 100000004862EUCTR2014-002150-39-BEovartis Pharma Services AG86
进行中（未招募）
1 期
Study of efficacy and safety of ligelizumab in adolescents and adults with chronic inducible urticaria who remain symptomatic despite treatment with H1- antihistaminesEUCTR2020-003018-11-SKovartis Pharma AG428
进行中（未招募）
1 期
A multi-center, randomized, double-blind, placebo and active controlled, parallel group study to evaluate the dose response of AHU377 in combination with valsartan 320 mg after 8 week treatment in patients with mild-to-moderate systolic hypertensioessential hypertensionMedDRA version: 13.1Level: PTClassification code 10015488Term: Essential hypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2010-022326-32-SKovartis Pharma Services AG910